J 2020

Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients ? results from real-life prospective study

HORŇÁK, Tomáš, Lukáš SEMERÁD, Daniela ŽÁČKOVÁ, Barbora WEINBERGEROVÁ, Zuzana ŠUSTKOVÁ et. al.

Basic information

Original name

Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients ? results from real-life prospective study

Authors

HORŇÁK, Tomáš (703 Slovakia, belonging to the institution), Lukáš SEMERÁD (203 Czech Republic, belonging to the institution), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Zuzana ŠUSTKOVÁ (203 Czech Republic, belonging to the institution), Jiřina PROCHÁZKOVÁ (203 Czech Republic), Petra BELOHLAVKOVA (203 Czech Republic), Lukas STEJSKAL (203 Czech Republic), Peter ROHON (203 Czech Republic), Edgar FABER (203 Czech Republic), Pavel ZAK (203 Czech Republic), Jiří MAYER (203 Czech Republic, belonging to the institution) and Zdeněk RÁČIL (203 Czech Republic, guarantor, belonging to the institution)

Edition

LEUKEMIA & LYMPHOMA, LONDON, TAYLOR & FRANCIS, 2020, 1042-8194

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.280

RIV identification code

RIV/00216224:14110/20:00115331

Organization unit

Faculty of Medicine

UT WoS

000489439400001

Keywords in English

serum lipids; cardiovascular risk; nilotinib and imatinib therapy

Tags

Tags

International impact, Reviewed
Změněno: 28/1/2021 14:12, Mgr. Tereza Miškechová

Abstract

V originále

Tyrosine kinase inhibitors (TKI) have dramatically improved the prognosis of CML patients with life expectancy close to individuals without CML [1], and therefore the longterm safety of TKIs has become especially important due to the potential for lifelong treatment. Nilotinib (NILO) tends to have a negative effect on lipid [2] and glucose [3] metabolism, while imatinib (IMA) seems to improve [4] these abnormalities. Although the data appear convincing, the real impact of these changes on cardiovascular (CV) risk and the development of CV complications during TKI therapy have not yet been confirmed.

Links

LM2018128, research and development project
Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)
Investor: Ministry of Education, Youth and Sports of the CR
NV17-30397A, research and development project
Name: Mutační analýza primitivních buněčných populací u chronické myeloidní leukémie: za hranicí BCR-ABL1